Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant β-catenin activation contributes to a third or more of human hepatocellular carcinoma (HCC), but β-catenin activation alone is not sufficient to induce liver cancer in mice.
|
25661872 |
2015 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant activation of the Wnt/β-catenin pathway is a major and frequent event in liver cancer, but inhibition of oncogenic β-catenin signaling has proven challenging.
|
26715116 |
2015 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our study uncovers a regulatory mechanism underlying liver cancer-specific Wnt transcriptional output, and suggests that TRIB2 functions as a signaling nexus to integrate the Wnt/β-catenin, Hippo/YAP, and C/EBPα pathways in cancer cells.
|
23769673 |
2013 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor effect of LATS2 on liver cancer death: Role of DRP1-mediated mitochondrial division and the Wnt/β-catenin pathway.
|
30981110 |
2019 |
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations.
|
25792709 |
2016 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BrMC can inhibit the functions and characteristics of LCSCs derived from the liver cancer MHCC97 cell line through downregulation of β-catenin expression.
|
24431896 |
2013 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we conclude that suppression of both Sirt1 and Wnt/βCatenin might be effective in treating liver cancer.
|
28583374 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with its enrichment for CTNNB1 mutations (69%), lncRNA profile of the CTNNB1-enriched EEC subgroup was highly similar to that of the CTNNB1-enriched liver cancer subgroup.
|
26431491 |
2015 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, using TOPflash and reverse transcription‑quantitative polymerase chain reaction analysis, Wnt/β‑catenin signaling and the transcriptional regulation of Wnt/β‑catenin target genes including dickkopf Wnt signaling pathway inhibitor 1, axis inhibition protein 2 and cyclin D1 were observed to be markedly upregulated in liver cancer SP cells.
|
26956539 |
2016 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry showed that all normal liver tissues and para-cancerous tissues examined showed membranous-type staining for beta-catenin protein, frequently with weak expression in the cytoplasm, but no beta-catenin accumulation in nuclei was found; while in liver cancer, 21 cases (61.8%) of HCC examined showed accumulated type in cytoplasms or nuclei.
|
11570580 |
2001 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the EBP50/beta-catenin complex promotes Wnt signaling, and over-expression of EBP50 may work cooperatively with beta-catenin in the development of liver cancer.
|
12830000 |
2003 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study revealed that the reciprocal regulation between O-GlcNAcylation and β-catenin facilitated the proliferation of liver cancer.
|
30762425 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we identified a number of candidate Wnt/beta-catenin target genes that can be useful for studying the role of altered Wnt signaling in liver cancer development, and showed that some of them might be direct targets of Wnt signaling in hepatoma cells.
|
17157329 |
2007 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockout of ASIC1a by CRISPR/CAS9 inhibited liver cancer cell proliferation and tumorigenicity in vitro and in vivo through β-catenin degradation and LEF-TCF inactivation.
|
27462920 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Let7b modulates the Wnt/β-catenin pathway in liver cancer cells via downregulated Frizzled4.
|
28671046 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway.
|
30359743 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mefloquine targets β-catenin pathway and thus can play a role in the treatment of liver cancer.
|
29578061 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation.
|
29383099 |
2017 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer.
|
17030191 |
2006 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results also indicated that AR cells increased abundantly in Tbx3, a downstream target of Wnt/β-catenin that it is implicated in liver cancer.
|
24317053 |
2013 |
Adult Liver Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and β-catenin pathways.
|
30418535 |
2019 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significantly, we also found that excessive β-catenin abrogated the effect of MEG3 in liver cancer.
|
29449541 |
2018 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
|
17283120 |
2007 |
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of β-Catenin.
|
31322782 |
2019 |
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The liver cancer-specific signature 16, associated with alcohol, displays a unique feature of transcription-coupled damage and is the main source of CTNNB1 mutations.
|
29101368 |
2017 |